<h1>Device firm reports strong 5-year valve outcomes, files draft red herring prospectus for high-risk equity share offering</h1> A medical device company reported 5-year clinical data for its transcatheter aortic valve, showing sustained safety, durability, and hemodynamic performance, with no structural valve deterioration or valve-related reinterventions. The study, a prospective, multicenter European trial, evaluated all-cause and cardiovascular mortality, stroke, pacemaker implantation, paravalvular leak, and valve function, and recorded acceptable long-term risk levels alongside improved functional status in patients. Separately, the company has filed a draft red herring prospectus with the Indian securities regulator for a proposed initial public offering of equity shares. The notice reiterates that the draft document is not for investment decisions and highlights the high-risk nature of such investments.